Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib-Reference-Cited by-同舟云学术

Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib

Published:2017-04 Issue: Volume:85 Page:149-158
ISSN:1357-2725
Container-title:The International Journal of Biochemistry & Cell Biology
language:en
Short-container-title:The International Journal of Biochemistry & Cell Biology

Author:

Bashash Davood,Safaroghli-Azar Ava,Dadashi Maryam,Safa Majid,Momeny Majid,Ghaffari Seyed H.

Publisher

Elsevier BV

Subject

Cell Biology,Biochemistry

Reference32 articles.

1. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: shedding new light on NVP-BKM120 mechanism of action;Bashash;Int. J. Biochem. Cell Biol.,2016

2. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function;Chen;Mol. Cell,2005

3. Phase I. study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia;Coutre;ASCO Annu. Meet. Proc.,2011

4. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches;De Luca;Expert Opin. Ther. Targets,2012

5. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells;Derenne;Blood,2002

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research;Cancers;2023-01-27

2. Synergistic Effects of PI3K Inhibition on Arsenic Trioxide Cytotoxicity in Acute Promyelocytic Leukemia Cells: A New Portrait of Idelalisib as an Adjuvant Therapy;Indian Journal of Hematology and Blood Transfusion;2022-10-26

3. Apoptin Overexpression Efficiently Amplified Cytotoxic Effects of PI3K Inhibition Using BKM120 in Lymphoblastic Leukemia Cell Lines;Advanced Pharmaceutical Bulletin;2021-07-10

4. The Superior Cytotoxicity of Dual Targeting of BCR/ABL and PI3K in K562 Cells: Proposing a Novel Therapeutic Potential for the Treatment of CML;Indian Journal of Hematology and Blood Transfusion;2021-04-01

5. EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells;Biochemical Pharmacology;2021-01